Early passaging of mesenchymal stem cells does not instigate significant modifications in their immunological behavior

BACKGROUND: Bone marrow-derived allogeneic mesenchymal stem cells (MSCs) from young healthy donors are immunoprivileged and their clinical application for regenerative medicine is under evaluation. However, data from preclinical and initial clinical trials indicate that allogeneic MSCs after transpl...

Descripción completa

Detalles Bibliográficos
Autores principales: Sareen, Niketa, Sequiera, Glen Lester, Chaudhary, Rakesh, Abu-El-Rub, Ejlal, Chowdhury, Subir Roy, Sharma, Vikram, Surendran, Arun, Moudgil, Meenal, Fernyhough, Paul, Ravandi, Amir, Dhingra, Sanjiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930635/
https://www.ncbi.nlm.nih.gov/pubmed/29720263
http://dx.doi.org/10.1186/s13287-018-0867-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930635/
https://www.ncbi.nlm.nih.gov/pubmed/29720263
http://dx.doi.org/10.1186/s13287-018-0867-4

Ejemplares similares